Comparison of sex steroid receptor analyses and carcinoembryonic antigen with clinical response to hormone therapy
✍ Scribed by Kenneth S. McCarty Jr.; Charles Cox; John S. Silva; Brett H. Woodard; Jeffrey A. Mossler; Darrow E. Haagensen Jr.; Thomas K. Barton; Kenneth S. McCarty Sr.; Dr. Samuel A. Wells Jr.
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 453 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
This study corroborates previous reports which suggested the efficacy of estrogen receptor (ER) analysis in predicting responses of patients with metastatic mammary carcinoma to hormonal therapeutic manipulation. The predictive value of multiconcentration titration and sucrose density gradient analyses of ERs and progesterone receptors (PRs) are compared. The predictive value of ER analyses can be improved by the discrimination of 8s versus 4 s binding species or by the use of PR analysis in combination with ER analysis. The tumor-associated antigen, carcinoembryonic antigen (CEA), is evolving as an important quantitative aid in evaluating the clinical responses of patients receiving hormonal therapy. Cancer 46:2846-2850, 1980. L I N I C A L REMISSION of metastatic breast cancer C following hormonal manipulative therapy was first demonstrated in 1896.2 Since that time it has been repeatedly
shown that 20 to 40% of patients with metastatic mammary carcinoma will respond to hormonal therapies. l9 A higher proportion of patients with long intervals from mastectomy to recurrence or with prior responses to hormonal therapy will respond to further hormonal alterations.
In 1961, Folca showed that patients whose mammary carcinomas concentrated H3 hexestrol in vivo were more likely to respond to a d r e n a l e ~t o m y . ~ Ten years